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Abstract Microalgal food supplements are becoming in-
creasingly popular due to their promising biological effects
and high nutritional value, evidenced in in vitro, in vivo, and
human studies. Some products of this kind have, however,
raised controversies concerning their safety. At the same time,
not much is known about the frequency of adverse events
following the use of microalgal supplements, potential factors
that may influence them, and general characteristics and be-
haviours of the consumer group. The present study aimed to
fill this gap and surveyed a group of Polish consumers of
microalgal products (n = 150) using an online questionnaire.
As found, microalgal supplements (Spirulina, Chlorella, and
Aphanizomenon) were popular in groups representing lacto-
ovo-vegetarianism and veganism and were consumed pre-
dominantly for nutritional, immune-boosting, and detoxifying
purposes. Their use was rarely discussed with specialists; the
Internet constituted the most important source of information
regarding these supplements. The most frequently self-
reported health-beneficial effects of supplementation included
the following: increased immunity, higher vitality, improved
hair and skin quality, and better general well-being. Diarrhoea,
nausea, abdominal pain, and skin rash were among the most
often reported adverse events. Pre-existing medical condi-
tions, namely renal failure and hypothyroidism, but not
Hashimoto’s thyroiditis, were associated with increased oc-
currence of side effects. Those individuals who had consulted
specialists as to the use of supplements reported adverse
events significantly less often. A strikingly high frequency
of side effects and very low consumer satisfaction were re-
por ted by a group of consumers supplement ing
Aphanizomenon-based products. In summary, the present
study highlights that microalgal consumers may benefit from
additional warnings of potential side effects and from consult-
ing a qualified health specialist prior to use.
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Introduction
Food supplements are increasingly popular worldwide, in-
cluding those based on microalgae (Kennedy 2005; Bailey
et al. 2013). Most often, such products contain biomass of
cyanobacteria belonging to the genera of Arthrospira (sold
as ‘Spirulina’), former BAphanizomenon^ (sold as ‘AFA’),
and Nostoc or green algae representing the genera
Haematococcus, Dunaliella, and Chlorella (sold under the
same name) and are marketed for their nutritional value and
potential biological activity (Pulz and Gross 2004; Raposo
and de Morais 2015). In fact, they have been shown to be a
rich source of proteins, fatty acids, pigments, minerals, diges-
tive and restriction enzymes, and various vitamins (Christaki
et al. 2011; Gellenbeck 2012; Buono et al. 2014; Wells et al.
2016). As a good source of iron and bioavailable forms of
vitamin B12 (Nakano et al. 2010; De et al. 2011; Merchant
et al. 2015), they are potentially of high interest to individuals
on vegetarian diets which are becoming increasingly popular
in different populations (Dinu et al. 2016). Moreover, the pos-
itive effect of the aforementioned microalgae and their ingre-
dients on a lipid profile as well as immunomodulatory, anti-
bacterial, antidiabetic, antioxidant, and antitumour activities
have been demonstrated not only in in vitro and in vivo
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experimental models but also, partially, in randomized clinical
trials (Ramamoorthy and Premakumari 1996; Yamani
et al. 2009; Anwer et al. 2012, 2013; Kwak et al. 2012;
Torres-Durán et al. 2012; Panahi et al. 2013; Mazokopakis
et al. 2014; Ryu et al. 2014). It has been further shown that
Chlorella may be efficiently used in adjunctive therapy for
depressive disorders (Panahi et al. 2015) whereas Spirulina
intake can significantly increase CD4 cells and reduce the
viral load in human immunodeficiency virus infections
(Ngo-Matip et al. 2015). Altogether, the existing data supports
the use of somemicroalgal food supplements as nutraceuticals
for a wide range of potential health-beneficial applications.
It has been, however, reported that the quality of some
microalgal supplements may be doubtful due to the presence
of cyanotoxins such as anatoxin-a or microcystins (Jiang et al.
2008; Rellán et al. 2009; Manali et al. 2016), elevated concen-
trations of toxic metals including aluminium, nickel, and lead
(Al-Dhabi 2013; Rzymski et al. 2015), and inorganic arsenic
species (Hedegaard et al. 2013). The former issue may result
from improper culture purity and the co-occurrence of poten-
tially toxic cyanobacteria species, e.g. Microcystis aeruginosa
(Vichi et al. 2012), while the latter two could be a consequence
of an unsuitable location of cultivation ponds (e.g. near rural,
industrial, or agricultural areas) and/or the use of certain
chemicals (e.g. aluminium-based flocculants) to harvest the
biomass (Papazi et al. 2010; Salim et al. 2011; Rzymski et al.
2015). Further, microalgal supplements may be potentially un-
suitable for some individuals, particularly those suffering from
renal failure due to high protein and phosphorus content (Kay
1991) or severe autoimmune disease, as a relapse of symptoms
may occur (Lee and Werth 2004).
Microalgal formulas, like any other food supplements, are
considered as foodstuffs, and contrary to medical products,
their registration requires neither preclinical nor clinical stud-
ies. Generally, it can be considered as definitely less strict than
that for pharmaceutical drugs (DSHEA 1994; Commission
Directive 2002/46/EC). Moreover, food supplements are usu-
ally self-prescribed, and there is no responsibility to report
side effects associated with their use. Consequently, the oc-
currence of adverse events, interactions with medicinal drugs,
or effects on certain disorders are less controlled for these
products. As far as microalgal supplements are concerned,
the only available data regarding undesirable consequences
have been presented in the form of a few case reports pub-
lished in peer-reviewed journals and as a summary on the side
effects of Spirulina use prepared by The Dietary Supplements
Information Expert Committee of the United States
Pharmacopeial Convention in 2011 (Marles et al. 2011). All
in all, there remained a need to evaluate the frequency of side
effects related to the consumption of these products in differ-
ent populations, preferably accompanied by some specifica-
tion of the consumer group and reasons behind their choice to
use microalgal food supplements.
To address these issues, the present study identified and
characterized a group of consumers of microalgal food sup-
plements in Poland and evaluated their attitudes, behaviour,
and intentions towards the use of these products. Currently,
Poland represents the largest and most dynamic market for
food supplements in central Europe due to the size of the
population and a very high level of spending (PMR 2016).
Numerous products containing microalgae, predominately
Spirulina and Chlorella, of various regions of origin, are
widely available, not only in pharmacies but also in organic
product stores, grocery shops, and supermarkets, as well as
through online sales. Considering the increasing popularity of
microalgal food products in Poland and recently reported
cases of adverse events following the concomitant consump-
tion of certain Spirulina and Chlorella formulas (Rzymski
et al. 2015), it appeared important to further assess the fre-
quency of side effects, consumer satisfaction level, and poten-




To explore consumers’ behaviours towards the use of
microalgal supplements and evaluate their experience with
these products, an online survey was conducted. As previous-
ly indicated, research based on online questionnaire creates
opportunity to collect data nationwide and to reach specific
and difficult-to-access groups of individuals (Wright 2005;
Rzymski and Królczyk 2016).
The present study employed an anonymous, structured,
online questionnaire that concerned:
(i) Consumer behaviours regarding types and forms (pills,
tablets, and powder) of microalgal supplements, dosages
in which they were taken, and whether a medical doctor
or pharmacist was consulted prior to consumption
(ii) Consumer intention(s) behind the use of microalgal
supplements
(iii) Main sources from which customers learned about the
bioactivity of microalgal supplements
(iv) The frequency of side effects following the use of
microalgal supplements as observed by consumers
(v) Consumer satisfaction with the supplement they used
and whether they would recommend them to others
(vi) Health-beneficial effects of microalgal supplement use
as observed by participants
The demographic characteristics of surveyed individ-
uals were also assessed and included the following: age,
gender, economical status, education, type of diet and
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body mass index (BMI; calculated from weight and height
reported in the questionnaire), medical history, and con-
comitant use of pharmaceutical drugs during the supple-
mentation period.
A questionnaire was made available online for a period
of 1 year (June 2015–July 2016). To reach the greatest
number of consumers, invitations to complete the ques-
tionnaire were frequently made through social media, web
portals, and message boards and were distributed through
academia and scientific societies in Poland.
Statistical analyses
The statistical analyses were performed using Statistica
v.10.0 (StatSoft, USA). Pearson’s chi-squared test was
used to compare the frequencies of the answers among
the different groups. Because age and BMI of individuals
did not meet the assumption of Gaussian distribution
(tested with the Shapiro–Wilk method), the non-
parametric Mann–Whitney U test was applied to evaluate
the effect of these variables on given answers. P val-
ue < 0.05 was considered as statistically significant.
Results
Demographic characteristics
The demographic characteristics of the participants are pre-
sented in Table 1. A total of 150 Polish individuals who used
microalgal food supplements in the past were considered in
this study. The participants had mean age of 35 years, were
mostly female, had normal BMI, had tertiary education, and
had moderate economic status. Although most individuals
were on an omnivorous diet, relatively high incidence of veg-
etarians (lacto-ovo-vegetarians and vegans) representing
42.7% was noted (Table 1). Kidney failure was declared by
2.7% (n = 4) of the participants and hypothyroidism and
Hashimoto’s thyroiditis by 3.3% (n = 5), each. All individuals
from the latter two groups used levothyroxine sodium. Other
concomitant drug intakes included the following: lithium
(n = 1) and perindopril (n = 1) with Chlorella, betahistine
(n = 1), and diosmin (n = 1) with Spirulina.
Most of the study participants used Spirulina supplements
(n = 85; 56.7%);Chlorellawas used by 30.0% (n = 45) where-
as formulas based on Aphanizomenon by 13.3% (n = 20).













Age (years) (mean ± SD) 34.0 ± 12.7 35.8 ± 8.3 34.1 ± 5.9 34.6 ± 10.8
Gender
Female (n/%) 65/76.5 37/82.2 12/60.0 114/76.0
Male (n/%) 20/23.5 8/17.7 8/40.0 36/24.0
BMI
Mean ± SD 22.8 ± 4.1 22.5 ± 3.3 22.3 ± 3.5 22.6 ± 3.8
Diet
Omnivore (n/%) 55/64.7 24/53.3 7/35.0 86/57.3
Lacto-ovo-vegetarian
(n/%)
19/22.4 9/20.0 6/30.0 34/22.7
Vegan (n/%) 11/12.9 12/26.7 7/35.0 30/20.0
Education
Secondary (n/%) 27/31.8 13/28.9 6/30.0 46/30.7
Tertiary (n/%) 58/68.2 32/71.1 14/70 104/69.3
Economical status
Low (n/%) 5/5.9 4/8.9 0/0.0 9/6.0
Moderate (n/%) 65/76.5 32/71.1 14/70.0 111/74.0
High (n/%) 15/17.6 9/20.0 6/30.0 30/20.0
Medical history
Kidney failure (n/%) 3/3.5 1/2.2 0/0.0 4/2.7
Hypothyroidism (n/%) 2/2.4 2/4.4 1/5.0 5/3.3
Hashimoto’s thyroiditis
(n/%)
3/3.5 2/4.4 0/0.0 5/3.4
SD standard deviation
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were used (65.3%), followed by powder (24.7%) and capsules
(10.0%). The majority of surveyed individuals (74.6%) de-
clared that they had been using supplements for no longer than
3 months; 13.3% had been using them for up to half a year,
4.0% up to 1 year, and 8.0% for longer.
Consumer behaviour
As declared by the surveyed individuals, microalgal supple-
ments were used for different purposes among which the most
popular were the following: supporting the immune function
(60.7%), providing nutrients (63.3%), and detoxication
(50.0%). A relatively significant number of individuals con-
sumed these products to improve general well-being (42.0%)
and skin and hair quality (39.3%), to support weight loss
(24.7%), and for physical regeneration (23.3%) (Fig. 1). The
reasons given for using supplements did not differ by dietary
group apart from nourishment being indicated more often by
lacto-ovo-vegetarians (76.5%) and vegans (76.6%) than om-
nivores (53.5%) (P < 0.05).
The Internet was identified by the vast majority of the stud-
ied group (69.3%) to be the main source of information on the
bioactivity of microalgal supplements. Medical doctors
(4.0%), dietitians (3.3%), and pharmaceutics (1.3%) were
one of the least important sources in this regard (Fig. 2).
Moreover, most of the participants (88.7%) did not consult
their supplementation with either a medical doctor or pharma-
cist, and none of the Aphanizomenon users did.
Generally, 46.0% of the participants stated that they used
the supplement at the dosage recommended on the label,
28.0% consumed them at higher or lower doses (14.0%
higher, 14.0% lower), while 26.0% were, in turn, unaware of
their exact daily intake. The declared daily doses ranged from
0.25 g (Spirulina) up to as much as 32 g (Aphanizomenon)
with an average intake around 4 g per day (Table 2).
Adverse effects
Overall, the occurrence of self-reported adverse effects in the
studied group was 28.7% (n = 43) but differed between par-
ticular supplement groups (P < 0.05). The lowest frequency
was observed for Chlorella users—17.8% (n = 8) with 15
different effects reported (Table 3). In this group, most of the
affected individuals (62.5%, n = 5) reported only one effect at
a time. Greater number of simultaneously occurring adverse
events were reported rarely by Chlorella users (two, seven, or
eight effects recorded by 2.2% (n = 1) consumers, each). A
slightly higher rate of adverse events, 22.4% (n = 19), was
observed for Spirulina consumers—a total of 21 effects were
reported (Table 3). Similar to Chlorella users, most of those
affected reported one effect at a time (47.4%, n = 10) but some
observed two (15.8%, n = 3), three (5.3%, n = 1), four (5.3%,
n = 1), five (10.5%, n = 2), six (10.5%, n = 2), and even seven
(5.3%, n = 1) simultaneously occurring effects. Diarrhoea was
the most common effect in groups of Spirulina and Chlorella
users. Up to 80% (n = 16) of individuals consuming
Aphanizomenon-based supplements reported at least one side
effect. From 16 events observed by these consumers, the
greatest frequency was noted for diarrhoea, nausea, abdominal
pain, and general weakness (Table 3). Most of those affected
reported four (25.0%, n = 4) and five (25.0%, n = 4)
Fig. 1 Reasons behind the use of microalgal food supplements in
surveyed consumers (n = 150)
Fig. 2 Sources of information on the bioactivity of microalgal
supplements among the surveyed consumers (n = 150)
Table 2 Daily intake doses [g] of microalgal-based food supplements
as declared by study participants (n = 115). Some individuals (n = 35)
were unaware of the dose at which the supplement was taken. The









Mean± SD 3.7 ± 3.0 4.1 ± 3.2 6.8 ± 9.3 4.2 ± 4.1
Median 3.0 3.0 3.0 3.0
Min–max 0.25–16.0 1.0–15.0 2.0–32.0 0.25–32.0
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simultaneously occurring effects. One or two effects at a time
were observed by 12.5% (n = 2) individuals, each; six or 12 by
6.25% (n = 1), each. Additionally, 6.7% (n = 3) and 8.2%
(n = 7) of Chlorella and Spirulina consumers, respectively,
reported a metallic taste in the mouth following their con-
sumption of the supplement; none noted it after the use of
Aphanizomenon supplement. Individuals reporting side ef-
fects declared that they had been using microalgal supplement
for no longer than 1 month.
Consumer age, BMI, and gender had no significant effect on
the occurrence of any of the adverse events in any supplement
group (P > 0.05 in all cases). The frequency of self-reported
adverse events was also unaffected by the supplement form (tab-
lets, pills, or powder) and consumed doses, regardless of the
supplement group (P > 0.05 in all cases). Within the Spirulina
group, adverse effects were significantly more often encountered
(P < 0.05) by vegans (63.6%) than lacto-ovo-vegetarians (5.3%)
and omnivores (0.0%). Importantly, all individuals (n = 3) suf-
fering from kidney failure and consuming Spirulina products
reported side effects: diarrhoea (n = 2) and headache (n = 1).
The only identified Chlorella consumer with kidney failure re-
ported a variety of adverse events including headache, muscle
pain, fever, insomnia, hearing and vision problems, and general
weakness. No significantly increased total frequency of side ef-
fects was observed for Hashimoto’s thyroiditis subjects (only a
single individual reported nausea after using Chlorella)
compared to healthy subjects (P > 0.05). An increased rate of
these effects was, however, found for hypothyroidism; four of
five (80%) individuals noted them. In this group, one person
reported headaches, dizziness, nausea, bone pain, skin rash, and
general weakness following the use of Spirulina, while a second
individual reported diarrhoea. Constipation, abdominal pain,
headaches, dizziness, bone and muscle pain, skin rash, and gen-
eral weakness were reported by one person after usingChlorella.
Finally, one hypothyroic subject consuming Aphanizomenon
supplement reported diarrhoea, abdominal pain, nausea, hypo-
tension, and skin rash. The patient consumingChlorella concom-
itantly with lithium reported diarrhoea and nausea. No side ef-
fects were reported by patients using Spirulina with diosmin
(n = 1) or betahistine (n = 1) and Chlorella with perindopril
(n = 1). Adverse effects were encountered significantly less often
by individuals consulting a medical doctor or pharmacist about
the microalgal supplementation than in the group of those who
did not consult one (5.9 vs 31.6%, P < 0.05).
Beneficial effects and consumer satisfaction
A number of beneficial effects, with varying frequencies, were
reported by the group using Spirulina- (total of 16 effects) and
Chlorella-based (total of 13 effects) supplements (Table 4). The
most often reported positive outcomes from the former group
included higher vitality, immunity boost, improved general
Table 3 Adverse events self-
reported by microalgal consumers
(n = 150)
Spirulina (n = 85) Chlorella (n = 45) Aphanizomenon (n = 20)
% (n)
Abdominal pain 7.0 (6) 2.2 (1) 40.0 (8)
Appetite loss 1.2 (1) – 15.0 (3)
Bone pain 2.4 (2) 2.2 (1) –
Constipation 4.7 (4) 6.6 (3) 5.0 (1)
Diarrhoea 12.9 (11) 6.6 (3) 70.0 (14)
Dizziness 2.4 (2) 2.2 (1) 10.0 (2)
Dysuria 1.2 (1) – –
Fever 2.4 (2) 2.2 (1) 10.0 (2)
General weakness 7.0 (6) 4.4 (2) 40.0 (8)
Headache 7.0 (6) 4.4 (2) 5.0 (1)
Hearing problems 1.2 (1) 2.2 (1) –
Hypertension 2.4 (2) – –
Hypotension 1.2 (1) – 10.0 (2)
Insomnia 1.2 (1) 2.2 (1) 15.0 (3)
Muscles pain 2.4 (2) 4.4 (2) 5.0 (1)
Nausea 10.6 (9) 2.2 (1) 50.0 (10)
Skin itching 3.5 (3) 2.2 (1) 10.0 (2)
Skin rash 7.0 (6) 4.4 (2) 10.0 (2)
Tachykardia 1.2 (1) – 5.0 (1)
Vision problems 1.2 (1) 2.2 (1) –
Vomiting 2.4 (2) 0.0 (0) 20.0 (4)
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well-being, and better skin quality. Most of the Spirulina con-
sumers (54.1%) were satisfied with the supplement (12.9% were
dissatisfied and 32.9% could not unambiguously decide), and
most of them (58.8%) would recommend its use (11.8% would
not and 29.4% could not unambiguously decide). The Chlorella
users declared better skin quality and general well-being, higher
vitality, and improvement with defecation with the greatest fre-
quencies. Similar to Spirulina, most of the consumers (55.6%)
were satisfied with their consumedChlorella supplement (13.3%
were dissatisfied and 31.1% could not unambiguously decide)
whereas 57.8%would recommend its use (13.3%would not and
28.9% could not unambiguously decide). In turn, individuals
using Aphanizomenon-based supplements did not observe any
beneficial effects of supplementation, none of themwere satisfied
with these products (85.0% were not satisfied and 15.0% could
not unambiguously decide), and 80.0% would not recommend
them to others (20.0% could not unambiguously decide).
Discussion
The present study has provided the insight into the world of
microalgal consumers. It identifies their basic demographic
characteristic, motivations and other behaviours behind the
use of microalgal supplements (with significance for the
industry), self-reported beneficial effects of supplementation
(relevant for research on the bioactivity of microalgae), the
daily doses at which these supplements are taken, and the
frequency of adverse events following the use of particular
types of microalgal formulas (important for product safety
evaluation). However, further investigations should be con-
ducted to ensure that these microalgal supplements are the
cause of the adverse effects as well as benefits.
Microalgal supplements are classified and regulated as
foodstuffs although their labelling in the EU and other world
regions requires certain particulars among which are the fol-
lowing: (i) the portion of the product recommended for daily
consumption, (ii) a warning not to exceed the stated recom-
mended daily dose, and (iii) a statement to the effect that food
supplements should not be used as a substitute for a varied diet
(Directive 2002/46/EC). It is highly advisable that consumers
comply with and not exceed the recommended doses. All
microalgae contain high protein and chlorophyll content
which at excess can cause gastrointestinal issues such as diar-
rhoea, nausea, or cramps (Garlick 2004) and high levels of
phosphorus of which excessive intake can have deleterious
effects on the kidneys (Uribarri and Calvo 2013). Moreover,
all microalgal supplements represent a rich source of iron;
overloading of which has also been associated with gastroin-
testinal distress (Frykman et al. 1994) as well as the generation
of reactive oxygen species through Fenton and Haber–Weiss
reactions and subsequent oxidative stress (Galaris and
Pantopoulos 2008). Elevated intake of manganese, which is
also present at high concentrations in microalgal supplements,
can, in turn, exhibit neurotoxic effects (Neal and Guilarte
2013). Therefore, it is recommended that potential consumers
consult the use of these products with a medical doctor, a
pharmacist, or a professional dietitian and, preferably, precede
the supplementation with biochemical tests (e.g. iron status
and haemoglobin concentration). It is beyond any doubt that
the nutritional value of microalgae is high enough to be ben-
eficial (Khan et al. 2005; Buono et al. 2014; Merchant et al.
2015), but their safe use has to be individually justified by
evidence-based means rather than intuition. Further, the im-
munomodulatory effects of these supplements can be benefi-
cial for some individuals (Selmi et al. 2011; Kwak et al. 2012)
but are rather less desirable in patients suffering from autoim-
mune diseases such as pemphigus vulgaris (Lee and Werth
2004). The excessive or inappropriate use of any food supple-
ment can be harmful, thus consulting a health care provider
prior to use can only be beneficial (Marcus 2016).
One of the most striking findings of the present study is the
high incidence of side effects reported by consumers of
Aphanizomenon supplements. Besides gastrointestinal symp-
toms such as diarrhoea, nausea, or abdominal pain, which can
generally be classified as a low/moderate health threat, skin
rash and itching were also reported, indicating inducement of
generalized allergic reactions following the use of a
Table 4 Health benefits of microalgal supplement consumption as self-
reported by the users. None were reported for consumers of
Aphanizomenon-based products (n = 20)
Spirulina (n = 85) Chlorella (n = 45)
% (n)
Allergy relief 4.7 (4) –
Asthma relief 3.5 (3) –
Better general well-being 8.2 (7) 22.2 (1)
Better hair 8.2 (7) 4.4 (2)
Better skin 9.4 (8) 22.2 (10)
Cheilosis relief – 2.2 (1)
Feeling of satiety 5.9 (5) 4.4 (2)
Headache relief – 2.2 (1)
Higher vitality 17.6 (15) 20.0 (9)
Improved memory and focus – 2.2 (1)
Improved B12 vitamin status – 2.2 (1)
Improved iron status 1.2 (1) 4.4 (2)
Improvement with defecation 1.2 (1) 11.1 (5)
Increased immunity 14.1 (12) 2.2 (1)
Insomnia reduction 1.2 (1) –
Libido increase 1.2 (1) –
Normalized pressure 1.2 (1) –
Rectal itching relief 1.2 (1) –
Stopping cold 2.4 (2) –
Weight reduction 2.4 (2) 4.4 (2)
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supplement. Such allergenicity of detoxified Aphanizomenon
flos-aquae has already been shown in a human study
employing skin-prick testing, at a frequency of 12%
(Bernstein et al. 2011). In addition, commercial powder based
on biomass of A. flos-aquae harvested fromKlamath Lake has
been toxic to human dermal fibroblasts (Niccolai et al. 2016).
Moreover, it is worth highlighting that Aphanizomenon-based
supplements raise numerous controversies after hepatotoxic
cyclic peptides, microcystins, and neurotoxic alkaloid
anatoxin-a have been identified in some of these products
(Rellán et al. 2009). Microcystins have never been identified
in Aphanizomenon sp., and the presence of these compounds
most likely results from the co-occurrence of toxic species
(e.g. M. aeruginosa) in the environment in which the target
species is harvested from (Carmichael et al. 2000; Gilroy et al.
2000). However, the biosynthesis of anatoxin-a is known to
occur in the former ‘Aphanizomenon’ genus, e.g. in
Cuspidothrix (formerly Aphanizomenon) issatschenkoi,
which may be difficult to distinguish from A. flos-aquae by
means of morphological features only (Rapala et al. 1993;
Ballot et al. 2010). Further, some strains of A. flos-aquae have
been demonstrated to produce cylindrospermopsin alkaloid
(Preussel et al. 2006) and paralytic shellfish poisoning toxins
(Ferreira et al. 2001). Identification of these strains requires
analytical studies and/or molecular screening to exclude the
possibility of harvesting toxic forms, yet such an approach
remains more a subject of scientific investigation than part
of a thorough monitoring programme. Nevertheless, some
promising effects of Aphanizomenon supplementation such
as a decrease in blood glucose and glycated haemoglobin
levels in patients with type 2 diabetes (Sanaei et al. 2015)
and improved B12 status in vegan subjects have been demon-
strated (Baroni et al. 2009) but they may not overcome poten-
tial health threats. Altogether, it appears that these microalgal
products may require particularly strict monitoring in regard
to toxin content to ensure consumer safety.
The frequency of side effects following the use of Spirulina
and Chlorella was significantly lower than that for
Aphanizomenon supplements, although it still accounted for
18–22% of their consumers. The most frequently reported
events were non-serious and included diarrhoea, nausea, diz-
ziness, and headaches. These symptoms, along with vomiting
and abdominal cramps, were also the most common side ef-
fects identified in Spirulina users as indicated by a collective
report of existing data from FDA MedWatch, Health Canada,
Australian Adverse Event Reports, and Uppsala Monitoring
Centre (World Health Organization Collaborating Centre for
International Drug Monitoring) (Marles et al. 2011).
Additionally, more serious events have been recorded includ-
ing liver damage, transient ischemic attack, heart palpitations,
or severe parkinsonian syndrome (Marles et al. 2011). Prior to
the present study, there was no compiled data on adverse
symptoms associated with Chlorella use; the only events that
had been reported included a unique case of recurrent psycho-
sis (Selvaraj et al. 2013), five cases of photosensitization
(Jitsukawa et al. 1984), a single event of asthma (Ng et al.
1994), and skin rash and itching, nausea, vomiting, and mus-
cle and bone pain following the concomitant use of low doses
of Spirulina and Chlorella (Rzymski et al. 2015). It should be
stressed that Arthrospira sp. and Chlorella sp. are not known
to produce any known toxic metabolites and are generally
considered per se as safe for human consumption
(Hutadilok-Towatana et al. 2010; Yang et al. 2011). It is there-
fore plausible that the adverse events are mostly due to prod-
uct contamination—avoidable by maintaining quality assur-
ance and monitoring (Grobbelaar 2003; Rzymski et al. 2015;
Wells et al. 2016).
Little is known about the interactions between microalgal
supplements and medical drugs. It can only be hypothesized
that due to the immunostimulatory activity of microalgal com-
ponents, their intake may interfere with immunosuppressive
drugs although no clinical evidence exists in this matter. The
present study demonstrated a wide range of side effects of
Spirulina, Chlorella, and Aphanizomenon use in individuals
suffering from hypothyroidism. This finding is important if
one considers that hypothyroidism is a common disorder
and its prevalence is likely to increase globally (Gaitonde
et al. 2012). Conversely, the frequency of side effects was very
low in autoimmune Hashimoto’s thyroiditis although all indi-
viduals, similar to the hypothyroidism group, concomitantly
used levothyroxine sodium. Therefore, the observed effects
cannot be solely linked to the interaction between thyroid
hormone and bioactive ingredients ofmicroalgal supplements.
Further research is necessary to elucidate the potential risks
arising from the use of these products by hypothyroic subjects.
It came as no surprise that the Internet was the most impor-
tant source of information on microalgal food supplements, as
its influential role in diet and food promotion has already been
well documented (Pettigrew et al. 2013; Rzymski and
Królczyk 2016). The benefits of microalgae as food are wide-
ly promoted through different message boards, social media
websites, and diet-dedicated portals. It is highly important for
the microalgal industry to communicate information on the
bioactivity of supplements to the general public in an accurate
and evidence-based manner, avoiding misunderstandings,
over-interpretations, and hypes. For example, Heussner et al.
(2012) reported that some microalgal supplements were spe-
cifically marketed as a supportive treatment for patients with
attention-deficit hyperactivity disorder, although to date, no
study has proven such a use to be either effective or harmless
for such subjects.
In the present study, most of the consumers admitted to use
microalgal supplements to support their immune function and
provide nutrients. Both reasons are supported by existing ex-
perimental data and clinical trials (Park et al. 2008; Kwak et al.
2012; Wells et al. 2016); thus, they can be considered
J Appl Phycol
reasonable. However, half of the respondents declared that
their intention had been to use these products to remove toxins
(e.g. heavy metals) from the body, a claim which is not evi-
denced by a single scientific study but promoted by unreliable
Internet sources. There is also no data demonstrating that
microalgal supplements may support human fertility. Their
use in pregnancy was, in turn, tested only for Chlorella and
revealed no adverse effects on mother or offspring but signif-
icantly reduced leg swelling in the third trimester, while risk of
anaemia and proteinuria was noted (Nakano et al. 2010).
Although promising results were demonstrated in in vivo ro-
dent experimental models for Spirulina supplementation in
pregnancy (Pankaj 2015), one case study linked severe neo-
natal hypercalcaemia following maternal use of Spirulina
from the fourth month of pregnancy (Moulis et al. 2012).
Further human studies are required to assess the safety of these
products for pregnant women and their offspring. The benefi-
cial effect of supplementation on hair and skin quality is also
not directly evidenced but hypothetically plausible if one con-
siders the nutritional value of these supplements, particularly
high content of fatty acids and vitamins. In the present study, a
relatively high percentage of those participants declared that
Chlorella and Spirulina intake actually improved the quality
of their hair and skin; thus, further studies should be conduct-
ed to clinically validate such a function of microalgae.
Although the present study revealed some valuable infor-
mation on microalgal supplements, there are some limitations
and interpretation of the results should be approached with
caution. The anonymous and online character of the survey
excluded the possibility of verifying the data, particularly that
concerning the occurrence of adverse and beneficial effects,
on the clinical level. Thus, it is plausible that some data were
misinterpreted by the respondents or resulted from a placebo-
like effect. Moreover, the study did not evaluate the quality of
particular supplements that participants consumed, so one
cannot unambiguously conclude whether the adverse events
resulted from the interactions of natural microalgal constitu-
ents, product contamination (e.g. toxic metals, cyanotoxins
from culture-contaminated species, and bacterial contamina-
tion), or individual susceptibility. The study is also limited to
one country although it aimed to reach as many Polish con-
sumers of microalgal supplements as possible. Their total
number of 150 is relatively low for a country with a population
of over 38 million. On the other hand, it can be considered
satisfying if one considers specificity of the studied group and
that all microalgal products available in Poland are imported
(lack of internal production limits the popularity of these
products).
In summary, the present study highlights that microalgal
supplements are consumed mostly for their nutritional, im-
mune-boosting, and allegedly detoxifying activities, at differ-
ent, sometimes higher than recommended (up to 32 g daily),
doses. Their use is rarely discussed with specialists; it is rather
the Internet that provides the most important source of infor-
mation on these products. The side effects of supplementation
are mostly of mild character and are faced more frequently by
individuals with kidney failure and hypothyroidism and less
often by those who consult a medical doctor/pharmacist about
their use. Autoimmune Hashimoto’s thyroiditis was prelimi-
narily not found to be associated with increased frequency of
side effects of microalgal supplement consumption—the ob-
servation requiring further testing before final conclusion can
be drawn. The high frequency of adverse events and dissatis-
faction with product use in the group consuming
Aphanizomenon-based products raise questions concerning
the safety of these supplements. The study highlights the need
to monitor microalgal supplements for contamination and un-
derlines that labelling these products with warnings of poten-
tial side effects and recommendation to consult a qualified
health specialist (e.g. medical doctor, dietician, and pharma-
cist) prior to use would be of potential benefit for consumer
safety.
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